Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study

Weijun Fu ¹, Soo-Mee Bang ², Honghui Huang ³

¹Shanghai Changzheng Hospital, Shanghai, China.
²Seoul National University Bundang Hospital, Seongnam, South Korea.
³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
⁵First Hospital of Jilin University, Changchun, China.
⁶Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
⁷Chonnam National University Medical School, Hwasun, Jeollanamdo, South Korea.
⁸First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, Zhejiang, China.
⁹Tianjin Cancer Hospital, Tianjin, China.
¹⁰Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong.
¹¹Johnson & Johnson, Spring House, PA, USA.
¹²Johnson & Johnson, Beijing, China.
¹³IQVIA, Shanghai, China.
¹⁴Johnson & Johnson, Shanghai, China.
¹⁵Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. houjian@medmail.com.cn.
¹⁶Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. wangjx@ihcams.ac.cn.

⁰Shanghai Changzheng Hospital, Shanghai, China.

Annals of Hematology +

|

May 23, 2025

View abstract on PubMed

Summary

Daratumumab plus bortezomib/melphalan/prednisone (D-VMP) improved patient-reported outcomes in transplant-ineligible Asian patients with newly diagnosed multiple myeloma. D-VMP showed greater benefits in global health status and social functioning compared to VMP alone.

Area Of Science

Hematology
Clinical Oncology
Patient-Reported Outcomes Research

Background

Newly diagnosed multiple myeloma (NDMM) in transplant-ineligible Asian patients requires effective treatment strategies.
Patient-reported outcomes (PROs) are crucial for assessing treatment impact beyond clinical efficacy.
The OCTANS trial evaluated daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus VMP in this population.

Purpose Of The Study

To evaluate the impact of D-VMP compared to VMP on patient-reported outcomes (PROs) in transplant-ineligible Asian patients with NDMM.
To assess quality of life and symptom burden using validated questionnaires.

Main Methods

Phase 3 OCTANS study randomized 220 patients to D-VMP or VMP.
PROs assessed using EORTC QLQ-C30 and EQ-5D-5L questionnaires at scheduled intervals.
Mixed-effects model for repeated measures used to analyze treatment effects on PROs.

Main Results

Comparable PRO improvements from baseline were observed between D-VMP and VMP groups.
D-VMP demonstrated statistically significant improvements in Global Health Status (GHS) at 9 months (p=0.0443).
Significant improvements in social functioning and nausea/vomiting symptoms were noted with D-VMP at 12 months (p=0.0042 and p=0.0012, respectively).

Conclusions

Both D-VMP and VMP improved PROs in transplant-ineligible Asian patients with NDMM.
D-VMP showed superior improvements in GHS, social functioning, and nausea/vomiting symptoms compared to VMP.
These findings support D-VMP as a treatment option that positively impacts quality of life in this patient population.

Keywords:

Daratumumab Multiple myeloma Patient-reported outcomes Transplant-ineligible